Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Fulcrum Therapeutics (Nasdaq: FULC) will release its first quarter 2026 financial results on Monday, April 27, 2026, before U.S. markets open.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) will release its first quarter 2026 financial results on Monday, April 27, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss results and recent corporate developments.
Investors may register to receive dial-in details and a unique PIN; an audio webcast and archived replay will be available via the Investor Relations site at www.fulcrumtx.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – FULC
In the Apr 20 session, FULC declined 4.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Results date
- April 27, 2026
- First quarter 2026 financial results release before U.S. markets open
- Call time
- 8:00 a.m. ET
- Scheduled start time for Q1 2026 conference call and webcast
Previous Conferences,earnings Reports
-
Scheduled Q3 2025 results release and 8:00 a.m. ET conference call.
-
Announced Q1 2025 results date and related conference call/webcast.
-
Set Q4 and full-year 2024 results timing and investor call details.
-
Outlined Q3 2024 results release and corporate update webcast.
-
Announced Q2 2024 results date and 8:00 a.m. ET conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on the development of small molecule therapies that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.